ALS Ltd (ASX: ALQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
ALS Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
ALS Ltd (ASX: ALQ)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Broker Notes
4 ASX 200 stocks just upgraded by top brokers
Industrials Shares
This ASX 200 stock is down 14% since April, and a director just bought over $500k worth
Dividend Investing
2 ASX 300 shares trading ex-dividend this week
Share Fallers
Why ALS, IDP Education, Predictive Discovery, and Telix shares are falling
Share Market News
5 things to watch on the ASX 200 on Monday
Broker Notes
4 ASX 200 shares just upgraded by brokers, one with 18% upside
Broker Notes
Leading brokers name 3 ASX shares to buy today
Share Market News
5 things to watch on the ASX 200 on Monday
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why ALS, Centaurus Metals, Pilbara Minerals, and Westgold shares are rising today
Dividend Investing
3 ASX 200 shares trading ex-dividend next week
Frequently Asked Questions
-
Yes, ALS Ltd historically pays two partially or fully franked dividends a year.
-
ALS Ltd generally pays its shareholder dividends in July and December
-
ALS Ltd listed on the ASX on 18 July 1952.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
12 Jun 2024 | $0.1960 | 20.00% | Final | 02 Jul 2024 |
23 Nov 2023 | $0.1960 | 20.00% | Interim | 14 Dec 2023 |
09 Jun 2023 | $0.1940 | 10.00% | Final | 06 Jul 2023 |
24 Nov 2022 | $0.2030 | 0.00% | Interim | 16 Dec 2022 |
06 Jun 2022 | $0.1700 | 30.00% | Final | 04 Jul 2022 |
02 Dec 2021 | $0.1580 | 30.00% | Interim | 17 Dec 2021 |
07 Jun 2021 | $0.1460 | 70.00% | Final | 05 Jul 2021 |
26 Nov 2020 | $0.0850 | 100.00% | Interim | 16 Dec 2020 |
05 Jun 2020 | $0.0610 | 70.00% | Final | 06 Jul 2020 |
27 Nov 2019 | $0.1150 | 30.00% | Interim | 16 Dec 2019 |
03 Jun 2019 | $0.1150 | 35.04% | Final | 01 Jul 2019 |
29 Nov 2018 | $0.1100 | 20.00% | Interim | 18 Dec 2018 |
06 Jun 2018 | $0.0900 | 40.00% | Final | 02 Jul 2018 |
29 Nov 2017 | $0.0800 | 40.00% | Interim | 18 Dec 2017 |
07 Jun 2017 | $0.0000 | 0.00% | Final | 03 Jul 2017 |
05 Dec 2016 | $0.0550 | 60.00% | Interim | 21 Dec 2016 |
08 Jun 2016 | $0.0600 | 40.00% | Final | 01 Jul 2016 |
03 Dec 2015 | $0.0750 | 25.07% | Interim | 18 Dec 2015 |
11 Jun 2014 | $0.2000 | 50.00% | Final | 02 Jul 2014 |
07 Jun 2013 | $0.2700 | 50.00% | Final | 02 Jul 2013 |
05 Jun 2009 | $0.4250 | 0.00% | Final | 01 Jul 2009 |
01 Dec 2008 | $0.4250 | 58.82% | Interim | 17 Dec 2008 |
06 Jun 2008 | $0.5100 | 58.82% | Final | 01 Jul 2008 |
30 Nov 2007 | $0.2975 | 58.82% | Interim | 17 Dec 2007 |
06 Jun 2007 | $0.3570 | 58.82% | Final | 02 Jul 2007 |
29 Nov 2006 | $0.2380 | 58.82% | Interim | 15 Dec 2006 |
05 Jun 2006 | $0.2900 | 100.00% | Final | 03 Jul 2006 |
25 Nov 2005 | $0.2100 | 100.00% | Interim | 20 Dec 2005 |
04 Jun 2004 | $0.1900 | 100.00% | Final | 01 Jul 2004 |
28 Nov 2003 | $0.1400 | 100.00% | Interim | 19 Dec 2003 |
ALQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About ALS Ltd
ALS Ltd (ASX: ALQ) is one of the world's largest laboratory testing, inspection, certification, and verification businesses. It operates from around 350 sites across 65 countries.
Listed on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS's commodities segment traditionally generates the majority of the company's underlying earnings. It provides geochemistry, metallurgy, inspection, and mine site services for the mining industry globally.
The company also provides environmental, pharmaceutical, and food and beverage testing and certification. ALS Ltd has a multi-billion dollar market capitalisation and is part of the ASX 100.
ALQ Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 Oct 2024 | $14.45 | $0.05 | 0.35% | 659,860 | $14.52 | $14.66 | $14.44 |
08 Oct 2024 | $14.40 | $-0.16 | -1.10% | 726,465 | $14.46 | $14.52 | $14.25 |
07 Oct 2024 | $14.56 | $0.02 | 0.14% | 490,176 | $14.54 | $14.75 | $14.47 |
04 Oct 2024 | $14.54 | $0.26 | 1.82% | 1,183,932 | $14.21 | $14.57 | $14.03 |
03 Oct 2024 | $14.28 | $0.10 | 0.71% | 903,650 | $14.27 | $14.40 | $14.11 |
02 Oct 2024 | $14.18 | $-0.08 | -0.56% | 1,011,383 | $14.28 | $14.32 | $14.16 |
01 Oct 2024 | $14.26 | $-0.16 | -1.11% | 885,343 | $14.43 | $14.55 | $14.25 |
30 Sep 2024 | $14.42 | $0.09 | 0.63% | 1,627,817 | $14.29 | $14.59 | $14.23 |
27 Sep 2024 | $14.33 | $0.23 | 1.63% | 1,353,259 | $14.21 | $14.37 | $14.12 |
26 Sep 2024 | $14.10 | $0.37 | 2.69% | 1,701,461 | $13.79 | $14.11 | $13.77 |
25 Sep 2024 | $13.73 | $0.08 | 0.59% | 1,367,659 | $13.79 | $13.82 | $13.65 |
24 Sep 2024 | $13.65 | $-0.02 | -0.15% | 2,177,497 | $13.76 | $13.85 | $13.48 |
23 Sep 2024 | $13.67 | $-0.19 | -1.37% | 2,224,258 | $13.70 | $13.89 | $13.66 |
20 Sep 2024 | $13.86 | $0.19 | 1.39% | 4,817,716 | $13.80 | $13.98 | $13.45 |
19 Sep 2024 | $13.67 | $-1.28 | -8.56% | 6,657,527 | $13.85 | $13.85 | $13.09 |
18 Sep 2024 | $14.95 | $0.13 | 0.88% | 1,987,284 | $14.74 | $14.96 | $14.67 |
17 Sep 2024 | $14.82 | $-0.09 | -0.60% | 1,286,719 | $14.97 | $14.99 | $14.79 |
16 Sep 2024 | $14.91 | $-0.14 | -0.93% | 1,029,591 | $15.10 | $15.12 | $14.82 |
13 Sep 2024 | $15.05 | $0.40 | 2.73% | 1,449,079 | $14.80 | $15.10 | $14.75 |
12 Sep 2024 | $14.65 | $-0.29 | -1.94% | 2,476,216 | $15.04 | $15.05 | $14.59 |
11 Sep 2024 | $14.94 | $-0.02 | -0.13% | 1,345,525 | $14.96 | $14.98 | $14.69 |
10 Sep 2024 | $14.96 | $0.15 | 1.01% | 1,285,093 | $14.87 | $14.98 | $14.71 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
08 Aug 2024 | Nigel Garrard | Buy | 2,250 | $33,412 |
On-market trade.
|
31 Jul 2024 | Malcom Deane | Issued | 163,082 | $2,304,360 |
Issue of securities. 398,893 Rights
|
01 Jul 2024 | Malcom Deane | Expiry | 424 | $5,952 |
As advised by the company. 257,297 - Performance Rights
424 Performance Rights forfeited |
01 Jul 2024 | Malcom Deane | Exercise | 21,486 | $301,663 |
Conversion of securities. 2,35,811 - Performance Rights & Service Rights
|
01 Jul 2024 | Malcom Deane | Issued | 18,088 | $253,955 |
Issue of securities. 257,721 - Performance Rights
As per announcement on 04/07/2024. |
01 Jul 2024 | Malcom Deane | Buy | 21,486 | $301,663 |
Conversion of securities.
|
28 Jun 2024 | Nigel Garrard | Buy | 2,750 | $39,595 |
On-market trade.
|
23 May 2024 | Nigel Garrard | Buy | 4,550 | $63,572 |
On-market trade.
|
19 Dec 2023 | Nigel Garrard | Buy | 3,150 | $40,477 |
On-market trade.
|
23 Nov 2023 | Nigel Garrard | Buy | 3,250 | $40,007 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Nigel David Garrard | Non-Executive Deputy ChairmanNon-Executive Director | Jun 2023 |
Mr Garrard is an experienced executive with a track record across the fast-moving consumer goods and industrial/manufacturing sectors. He has over 20 years' experience as an ASX-listed CEO across three companies. In 2019, he retired as Managing Director and CEO of Orora Limited. He led the demerger of Orora Limited from Amcor, and the subsequent listing of Orora Limited on ASX in 2013. He was President of the Amcor Australasia and Packaging Distribution business group, Managing Director of Coca-Cola Amatil's Food and Services Division, and Managing Director of SPC Ardmona. Nigel brings international experience across listed, not-for-profit, government and private entities. He is currently the Chairman of Ansell Limited, a non-executive director of CSR Ltd, Chairman of Flinders Port Holdings Pty Ltd, and Chairman of the McMahon Services advisory board. He is the Chair of the People Committee.
|
Dr John Francis Mulcahy | Non-Executive Director | Feb 2012 |
Dr Mulcahy is Chairman of Orix Australia Corporation Limited, an unlisted public company (appointed March 2016), and Deputy Chairman of GWA Group Limited (appointed November 2010). He is also a current Non-Executive Director of Zurich Australia Insurance subsidiaries. John was previously a director and Chairman of both Mirvac Group Limited (November 2009 - December 2022) and Coffey International Limited (September 2009 - January 2016). He is a former Guardian of the Future Fund of Australia and former Managing Director and Chief Executive Officer of Suncorp-Metway Limited. Prior to Suncorp, John held executive roles at the Commonwealth Bank and Lend Lease Corporation. He is a member of the Sustainability and Innovation Committee.
|
Ms Tonianne Dwyer | Non-Executive Director | Jul 2016 |
Ms Dwyer has experience as a company director and executive working in finance, corporate strategy and mergers and acquisitions across a variety of sectors and international markets. She is an internationally experienced independent company director, having had a 25-year executive career in investment banking during which she held roles with Hambros Bank Limited and Societe General in the UK and Europe. Tonianne currently holds a non-executive directorship role with Incitec Pivot Limited (appointed May 2022). She is Deputy Chancellor of the Senate of the University of Queensland and is on the Board of the Sir John Monash Foundation. Her previous roles included non-executive director positions with OZ Minerals Limited, DEXUS Property Group and DEXUS Wholesale Property Fund. She is a member of the People Committee and a member of the Risk Committee.
|
Ms Leslie A Desjardins | Non-Executive Director | Nov 2019 |
Ms Desjardins has a background as a CFO and senior financial and governance professional in a range of multinational and global businesses. She has commercial and financial governance expertise with multinational public companies in North America, Canada and Australia, each with global operations. Her areas of expertise include CFO level executive and financial strategic leadership, M&A, corporate finance and treasury, governance, financial and tax compliance, and enterprise risk management. Leslie is currently a Director, Audit Committee Chair, Human Resource Committee member with Ansell Limited. Previously, she served as a Board Director and Audit Committee member with AptarGroup. During her executive career, Leslie served as Executive VP and CFO at Amcor Limited, a global leader in packaging of food, beverage, pharmaceutical and tobacco products. Prior to Amcor Ltd, Leslie served in financial and corporate strategic positions with General Motors Corporation, including Chief Financial Officer GM Holden Australia, Controller GM North America, Executive Director Manufacturing Finance and Director GM North America Strategy and Planning. She is the Chair of the Risk Committee, a member of the Sustainability and Innovation Committee.
|
Dr Siddhartha Kadia | Non-Executive Director | Jan 2019 |
Dr Kadia was formerly President and CEO of EAG Laboratories, a global scientific testing company headquartered in San Diego, California. He has also been a Director of USA-listed companies Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC), Nuvasive, Inc (appointed February 2022) and was CEO and a Director of PhenomeX (NSDQ: CELL). He is currently a Non- Executive Director of ATS (Applied Technical Services). Prior to EAG, Siddhartha served as President of the Life Sciences Division at Life Technologies Corporation (NSDQ: LIFE), a publicly traded life sciences tools company. Siddhartha was also a management consultant at McKinsey & Company where his work focused on life sciences and healthcare related engagements. Siddhartha has lived and worked in the US, Japan, China, and India and has more than 20 years of international experience as a company director, executive and technical leader in the Life Sciences and TIC (testing, inspection and certification) sectors. He is a Chair of the Sustainability and Innovation Committee, a member of the People Committee.
|
Ms Erica Mann | Non-Executive Director | Mar 2024 |
Ms Mann is an experienced C-suite executive with a 30-year career across complex, regulated, multi-channel and multi product environment in top DAX, NYSE, NSDAQ pharmaceutical, OTC and FMCG multinationals. Before retiring as an executive, Erica led Bayer's Consumer Health Division, one of the OTC companies. Prior to joining Bayer, she was President and General Manager of Pfizer Nutrition following its acquisition of Wyeth Inc, where she served as Senior Vice President of Global Nutrition. This followed other senior executive roles of other Fortune 500 companies including Eli-Lily and Johnson & Johnson. She has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the US. In addition to her executive experience in the nutrition and health industry, Erica has experience with global and emerging markets across Africa, China, Russia, and Brazil. Erica currently serves as an independent director of Perrigo, DSM-Firmenich and Kellogg (recently reincorporated as Kellanova) where she is a member of the Talent, Audit, and Social Responsibility & Public Policy Committees. Erica previously chaired the Board of the World Self-Medication Industry Association and served as an independent director with Blackmores Ltd and Solo-Flordis International.
|
Mr Peter Possemiers | Non-Executive Director | Nov 2022 |
Mr Possemiers has a background as a TIC sector expert with almost 40 years' experience working as a senior executive in leadership roles globally for SGS. He has lead teams both regionally and globally most notably SGS's global Environment Health and Safety business, a CHF 550 million business with a global headcount which exceeded 6,000. As Executive Vice President, he was a member of the SGS Operations Council with responsibility for the strategic growth and profitability of the business, leading 15 strategic acquisitions. He quickly moved into management roles in Singapore, Philippines, China and Korea, where he established and developed new markets including food, pharma, and mobile technology. In 2007, he was promoted to a role in Europe to manage the downstream OG&C business becoming the global market leader in this sector for SGS. In 2013, Peter was promoted to Executive Vice President,Global Environment, Health & Safety, a position based in Switzerland which he held for 8 years before moving into his most recent role as Vice President, Strategic Integration in 2021 following the acquisition of the Synlab A&S business, which covered the environmental, food, pharma and oil condition monitoring testing sector across Europe. He is a member of the Sustainability and Innovation Committee, and the Risk Committee.
|
Mr Malcom Deane | Chief Strategy Officer General Manager Life Sciences - Food & Pharma Americas GeneralChief Executive OfficerManaging Director | Mar 2023 |
Mr Deane has served the company in executive positions for the past 10 years in such roles as General Manager for Life Sciences Latin America, Food & Pharma Americas, and most recently as the Chief Strategy Officer, leading corporate strategy, business development and acquisitions.
|
Mr Michael Paul Pearson | Company Secretary | Dec 2017 |
-
|
Ms Dayna Field | Company SecretaryGeneral Counsel | Oct 2024 |
-
|
Stuart Hutton | Chief Financial Officer |
-
|
|
Michael Paul Pearson | Company Secretary |
-
|
|
Dayna Field | Company SecretaryGeneral Counsel |
-
|
|
Tim Kilmister | Executive General Manager Environmental |
-
|
|
Andreas Jonsson | Executive General Manager Food and Pharmaceutical |
-
|
|
Bruce McDonald | Executive General Manager Minerals |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited i | 136,403,040 | 28.18% |
Citicorp Nominees Pty Limited | 70,921,055 | 14.65% |
J P Morgan Nominees Australia Pty Limited | 70,607,766 | 14.59% |
BNP Paribas Noms Pty Ltd. | 24,099,533 | 4.98% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 12,963,781 | 2.68% |
BNP Paribas Nominees Pty Ltd. <Agency Lending A/C> | 10,906,425 | 2.25% |
National Nominees Limited | 9,081,446 | 1.88% |
Faircase Pty Ltd. | 8,049,878 | 1.66% |
Australian Foundation Investment Company Limited | 7,012,164 | 1.45% |
Washington H Soul Pattinson and Company Limited | 6,737,845 | 1.39% |
Argo Investments Limited | 5,104,023 | 1.05% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 3,235,312 | 0.67% |
Merrill Lynch (Australia) Nominees Pty Limited | 2,428,867 | 0.50% |
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd.> | 2,336,802 | 0.48% |
Netwealth Investments Limited <Wrap Services A/C> | 2,226,863 | 0.46% |
HSBC Custody Nominees (Australia) Limited Gsi Eda | 1,928,658 | 0.40% |
Ubs Nominees Pty Ltd. | 1,583,443 | 0.33% |
Ms Maryon Catherine Campbell <The Checkmate A/C> | 1,309,122 | 0.27% |
Mirrabooka Investments Limited | 1,209,500 | 0.25% |
HSBC Custody Nominees (Australia) Limited ii | 1,019,373 | 0.21% |